Drug Database
Back to search

Netherlands· NL-f7451471656e

Alacare 8 mg pleister voor cutaan gebruik

A aminolevulinic acid product containing 5-aminolevulinezuurhydrochloride, registered in Netherlands by Photonamic GmbH & Co. KG. The same ATC class is registered in 14 of our 19 countries.

ATC L01XD04

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedAlacare 8 mg pleister voor cutaan geb…ATCL01XD04REGISTER NO.NL-f7451471656ePACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about 5-aminolevulinezuurhydrochlorideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Aminolevulinic acid is registered in 14 of 19 countries.

Countries holding a registration under ATC L01XD04 (aminolevulinic acid), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search aminolevulinic acid products by name

Aminolevulinic acid · ATC L01XD04

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
5-AMINOLEVULINEZUURHYDROCHLORIDE
Manufacturer
Photonamic GmbH & Co. KG
Country
Netherlands (NL)
ATC code
L01XD04
ATC class
Aminolevulinic acid
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    113539

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

121 interactions on record for aminolevulinic acid.

Graded by severity as the source publishes them — 120 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check aminolevulinic acid against other medicinesHow interaction checks work

Aminolevulinic acid · interactions on record

121 records

  • 120 severe
  • 1 moderate

Most severe, free to view

  • MinocyclineA01AB23severe
  • SulfasalazineA07EC01severe
  • GlibenclamideA10BB01severe
  • ChlorpropamideA10BB02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Aminolevulinic acid in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All aminolevulinic acid products

Authorised across Europe · EMA

The same active substance is authorised in 17 EEA countries. Names it is sold under:

  • Austria · Alacare
  • Belgium · Effala
  • Czechia · Alacare
  • Germany · Alacare
  • Denmark · Alacare
  • Finland · Alacare
  • France · Effala
  • United Kingdom (Northern Ireland) · Alacare
  • Ireland · Alacare
  • Iceland · Ameluz, Gliolan
  • Italy · Alacare
  • Liechtenstein · Ameluz, Gliolan
  • Norway · Alacare, Ameluz
  • Poland · Alacare
  • Portugal · Alacare
  • Sweden · Alacare
  • Slovakia · Alacare

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/afad859e-0339-40b0-b4a7-12fce33f813e
GET /v1/drugs/afad859e-0339-40b0-b4a7-12fce33f813e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Pleister",
  "route": "Cutaan gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h113539_smpc.pdf",
  "strength": null,
  "atc_label": "Aminolevulinic Acid",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg113539",
  "excipients": [
    "COPOLYMEER VAN 2-ETHYLHEXYLACRYLAAT (62,2), METHACRYLAAT (32,0), ACRYLZUUR (5,7), GLYCIDYLMETHACRYLAAT (0,03)",
    "POLYESTERFOLIE, BEKLEED MET POLYETHYLEEN EN ALUMINIUM",
    "POLYETHYLEENTEREPHTHALAAT, GESILICONEERD"
  ],
  "substances": [
    "5-AMINOLEVULINEZUURHYDROCHLORIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h113539.pdf",
  "authorised_at": "2014/04/14",
  "procedure_number": "NL/H/2883/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "113539",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about aminolevulinic acid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console